Sublingual Bedtime Drug Candidate Improves Pain and Sleep in Fibromyalgia 

Summary: Tonix Pharmaceuticals presented new data at the American College of Rheumatology’s 2024 meeting, demonstrating that its drug candidate TNX-102 SL significantly reduces pain and improves sleep quality in fibromyalgia patients. In the phase 3 RESILIENT study, the drug met its primary endpoint and showed improvements across all secondary endpoints, including sleep and fatigue. Tonix…

Read More

Herbal Ingredient Increases Sleep Time by 39%, Study Finds

Summary: Karallief has introduced KaraCalm, a new herbal ingredient that has shown promising results in a 56-day clinical study for improving sleep quality and reducing stress. The randomized, double-blind study involving 60 participants demonstrated that the low-dose herbal supplement increased total sleep time by 39% and reduced stress-related markers, including cortisol levels, within just 14…

Read More

PDAC Contractor Approves HCPCS Code for GoodSleepCo Oral Appliance

The Pricing, Data Analysis, and Coding (PDAC) contractor has approved a Healthcare Common Procedure Coding System (HCPCS) code for billing the four Durable Medical Equipment Medicare Administrative Contractors for the GoodSleepCo hushd Pro Avera oral appliance. To bill Medicare for the GoodSleepCo appliance, use HCPCS code K1027 (oral device/appliance used to reduce upper airway collapsibility,…

Read More

Deltawave CPAP Mask Release Pushed to January 2025

Summary: REMSleep Holdings has announced a delay in the market release of its Deltawave nasal pillows CPAP mask, now anticipated to launch in January 2025. The company attributes the delay to challenges with regulatory compliance and supply chain coordination, particularly for critical materials like medical-grade silicone. Despite setbacks, REMSleep notes it remains focused on ensuring…

Read More

Findings Support Continuous ECG Monitoring for Detecting Sleep-Related Arrhythmias

Summary: iRhythm Technologies presented new data at the American Heart Association’s 2024 Scientific Sessions, highlighting the benefits of long-term continuous monitoring for detecting arrhythmias. The findings span three areas: identifying arrhythmia patterns during sleep and activity, leveraging digital tools to boost patient compliance, and assessing the economic impact of early arrhythmia detection in patients with…

Read More

Preclinical Program Investigates Potential of NLS’ Dual Orexin Agonists for

Summary: NLS Pharmaceutics Ltd is investigating two novel dual orexin receptor agonists (DOXAs), AEX-41 and AEX-2, in a preclinical study to assess their potential for treating narcolepsy. The research, conducted at the Centre for Neuroscience Research of Lyon, focuses on promoting wakefulness, enhancing sleep quality, and reducing cataplexy in an orexin knockout mouse model. By…

Read More